GlassScriptPhysician profile
George A Namey
NPI 1346247699
$6,007.55
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,983 · 2020: $626 · 2021: $1,877 · 2022: $521.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $957.06 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $653.26 | 2019-2022 | |
| Glaxosmithkline, LLC. | $502.24 | 2019-2022 | |
| Astellas Pharma US INC | $415.10 | 2019-2021 | |
| Lilly USA, LLC | $329.15 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.80 | 2019-2022 | |
| Amarin Pharma, INC. | $304.14 | 2019-2021 | |
| Pfizer INC. | $299.05 | 2019-2022 | |
| Novo Nordisk INC | $285.78 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $238.75 | 2019-2022 | |
| Esperion Therapeutics, INC. | $224.52 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $200.00 | 2019-2022 | |
| Allergan, INC. | $189.90 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.97 | 2019-2021 | |
| Abbvie INC. | $115.81 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $114.53 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.44 | 2019-2022 | |
| Abbott Laboratories | $88.71 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $76.61 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $60.06 | 2019-2022 | |
| Amgen INC. | $58.57 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $56.97 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $52.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.63 | 2021 | |
| Genentech USA, INC. | $20.28 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.08 | 2022 | |
| Endo Pharmaceuticals INC. | $16.13 | 2019 | |
| Grifols USA, LLC | $15.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.34 | 2019 | |
| Shire North American Group INC | $14.85 | 2019 | |
| Currax Pharmaceuticals LLC | $14.81 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.80 | 2019 | |
| Lucid Diagnostics INC. | $13.42 | 2022 | |
| Circassia INC. | $12.38 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Namey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.